Alogliptin | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Alogliptin | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | |
Alogliptin | hsa00500 | Starch and sucrose metabolism | 6.17E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Alogliptin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Alogliptin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Alogliptin | hsa00730 | Thiamine metabolism | 2.27E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Alogliptin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Alogliptin | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
Alogliptin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Alogliptin | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Alogliptin | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | |
Alogliptin | hsa03020 | RNA polymerase | 3.00E-02 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | |
Alogliptin | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
Alogliptin | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
Alogliptin | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | |
Alogliptin | hsa04020 | Calcium signaling pathway | 3.61E-02 | 4 | Q96DU7, Q08828, Q13557, P21860 | ITPKC, ADCY1, CAMK2D, ERBB3 | More | |
Alogliptin | hsa04064 | NF-kappa B signaling pathway | 2.35E-02 | 4 | P01584, P63279, Q8NHW4, Q9NQC7 | IL1B, UBE2I, CCL4L2, CYLD | More | |
Alogliptin | hsa04070 | Phosphatidylinositol signaling system | 1.53E-02 | 2 | Q86XP1, Q96DU7 | DGKH, ITPKC | More | |
Alogliptin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Alogliptin | hsa04141 | Protein processing in endoplasmic reticulum | 2.78E-02 | 3 | P07384, O95487, O95816 | CAPN1, SEC24B, BAG2 | More | |
Alogliptin | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | |
Alogliptin | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | |
Alogliptin | hsa04213 | Longevity regulating pathway - multiple species | 2.82E-02 | 3 | Q08828, P51828, P0DMV8 | ADCY1, ADCY7, HSPA1A | More | |
Alogliptin | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Alogliptin | hsa04270 | Vascular smooth muscle contraction | 9.46E-04 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | |
Alogliptin | hsa04310 | Wnt signaling pathway | 1.79E-02 | 2 | P17612, P67870 | PRKACA, CSNK2B | More | |
Alogliptin | hsa04340 | Hedgehog signaling pathway | 3.91E-02 | 1 | P17612 | PRKACA | More | |
Alogliptin | hsa04360 | Axon guidance | 1.50E-02 | 3 | P20827, P23528, Q06124 | EFNA1, CFL1, PTPN11 | More | |
Alogliptin | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | |
Alogliptin | hsa04530 | Tight junction | 1.74E-03 | 6 | P63261, P16989, P56750, Q9Y478, Q92974, Q14247 | ACTG1, CSDA, CLDN17, PRKAB1, ARHGEF2, CTTN | More | |
Alogliptin | hsa04611 | Platelet activation | 2.12E-02 | 2 | Q9Y490, P17612 | TLN1, PRKACA | More | |
Alogliptin | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Alogliptin | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | |
Alogliptin | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | |
Alogliptin | hsa04657 | IL-17 signaling pathway | 1.36E-02 | 5 | O00463, Q16539, P49841, P14780, P01375 | TRAF5, MAPK14, GSK3B, MMP9, TNF | More | |
Alogliptin | hsa04664 | Fc epsilon RI signaling pathway | 1.74E-03 | 4 | P01375, Q16539, Q9UQC2, P20292 | TNF, MAPK14, GAB2, ALOX5AP | More | |
Alogliptin | hsa04668 | TNF signaling pathway | 8.30E-04 | 9 | P01375, Q12933, O00463, Q16539, Q99941, P01584, P20749, P14780, O95429 | TNF, TRAF2, TRAF5, MAPK14, CREBL1, IL1B, BCL3, MMP9, BAG4 | More | |
Alogliptin | hsa04713 | Circadian entrainment | 4.25E-02 | 3 | Q13557, Q02153, Q08828 | CAMK2D, GUCY1B3, ADCY1 | More | |
Alogliptin | hsa04714 | Thermogenesis | 1.25E-02 | 3 | P15336, P63261, Q9Y478 | ATF2, ACTG1, PRKAB1 | More | |
Alogliptin | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Alogliptin | hsa04742 | Taste transduction | 3.91E-02 | 1 | P17612 | PRKACA | More | |
Alogliptin | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.23E-03 | 5 | P01584, Q08828, P51828, Q13557, P0DP23 | IL1B, ADCY1, ADCY7, CAMK2D, CALM1 | More | |
Alogliptin | hsa04911 | Insulin secretion | 2.23E-02 | 3 | Q08828, Q99941, Q13557 | ADCY1, CREBL1, CAMK2D | More | |
Alogliptin | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | |
Alogliptin | hsa04920 | Adipocytokine signaling pathway | 2.80E-02 | 2 | Q06124, Q9Y478 | PTPN11, PRKAB1 | More | |
Alogliptin | hsa04932 | Non-alcoholic fatty liver disease | 1.04E-04 | 11 | P01375, P49841, O43521, P48023, O75460, Q12933, P01584, P13073, P12074, O15239, O95298 | TNF, GSK3B, BCL2L11, FASLG, ERN1, TRAF2, IL1B, COX4I1, COX6A1, NDUFA1, NDUFC2 | More | |
Alogliptin | hsa04934 | Cushing syndrome | 6.07E-03 | 4 | Q99941, Q08828, O15169, Q13557 | CREBL1, ADCY1, AXIN1, CAMK2D | More | |
Alogliptin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Alogliptin | hsa04962 | Vasopressin-regulated water reabsorption | 7.22E-03 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | |
Alogliptin | hsa04970 | Salivary secretion | 4.78E-02 | 3 | Q08828, P51828, P0DP23 | ADCY1, ADCY7, CALM1 | More | |
Alogliptin | hsa04976 | Bile secretion | 4.78E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | |
Alogliptin | hsa05010 | Alzheimer disease | 1.23E-02 | 8 | Q92542, O15239, P05496, P12074, P01584, Q12933, O15169, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, IL1B, TRAF2, AXIN1, PSMC4 | More | |
Alogliptin | hsa05012 | Parkinson disease | 3.53E-02 | 6 | P62987, O15239, P12074, P05496, P43686, Q13557 | UBA52, NDUFA1, COX6A1, ATP5G1, PSMC4, CAMK2D | More | |
Alogliptin | hsa05014 | Amyotrophic lateral sclerosis | 2.99E-02 | 7 | O15239, P12074, P05496, Q12933, P43686, P37198, P35658 | NDUFA1, COX6A1, ATP5G1, TRAF2, PSMC4, NUP62, NUP214 | More | |
Alogliptin | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | |
Alogliptin | hsa05020 | Prion disease | 2.99E-02 | 7 | P01584, P46531, O15239, P05496, P12074, P43686, Q99941 | IL1B, NOTCH1, NDUFA1, ATP5G1, COX6A1, PSMC4, CREBL1 | More | |
Alogliptin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 9.10E-03 | 9 | O15239, P12074, P05496, Q12933, O15169, P01584, Q13557, P62987, P43686 | NDUFA1, COX6A1, ATP5G1, TRAF2, AXIN1, IL1B, CAMK2D, UBA52, PSMC4 | More | |
Alogliptin | hsa05034 | Alcoholism | 1.96E-04 | 6 | Q96RR4, Q93077, P62807, O60814, P84243, P68431 | CAMKK2, HIST1H2AC, HIST1H2BC, H2BC12, H3F3A, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Alogliptin | hsa05110 | Vibrio cholerae infection | 2.11E-03 | 2 | Q99437, P17612 | ATP6V0B, PRKACA | More | |
Alogliptin | hsa05130 | Pathogenic Escherichia coli infection | 9.80E-03 | 4 | Q92974, P63261, Q06124, O95487 | ARHGEF2, ACTG1, PTPN11, SEC24B | More | |
Alogliptin | hsa05134 | Legionellosis | 2.82E-02 | 3 | P01584, Q9NR31, P0DMV8 | IL1B, SAR1A, HSPA1A | More | |
Alogliptin | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Alogliptin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Alogliptin | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | |
Alogliptin | hsa05163 | Human cytomegalovirus infection | 2.22E-03 | 13 | P01375, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, O00463 | TNF, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, TRAF5 | More | |
Alogliptin | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
Alogliptin | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Alogliptin | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
Alogliptin | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Alogliptin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Alogliptin | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Alogliptin | hsa05418 | Fluid shear stress and atherosclerosis | 1.08E-03 | 7 | Q16539, Q14145, P10599, P14780, P01375, P14778, P27930 | MAPK14, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |